123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254 |
- % Bioinformatic analysis of complex, high-throughput genomic and epigenomic data in the context of $\mathsf{CD4}^{+}$ T-cell differentiation and diagnosis and treatment of transplant rejection
- % Ryan C. Thompson \
- Su Lab \
- The Scripps Research Institute
- % October 24, 2019
- # Intro
- # Biological motivation: Transplant rejection
- ## Organ transplants are a life-saving treatment for many
- \Large
- * 36,528 transplants performed in the USA in 2018[^1]
- . . .
- * 100 transplants every day!
- . . .
- * Over 113,000 people on the national transplant waiting list as of
- July 2019
- [^1]: Source: https://www.organdonor.gov/statistics-stories/statistics.html
- ## Organ transplants are a life-saving treatment for many
- ![Organ donation statistics for the USA in 2018[^2]](graphics/presentation/transplants-organ-CROP.pdf){ height=70% }
- [^2]: Source: https://www.organdonor.gov/statistics-stories/statistics.html
- ## Rejection is an adaptive immune response against a graft
- * The host's adaptive immune system identifies and attacks cells
- bearing non-self antigens
- . . .
- * An allograft contains differnet genetic variants from the host,
- resulting in protein-coding differences
- . . .
- * Left unchecked, the host immune system eventually notices these
- alloantigens and begins attacking (rejecting) the graft
- . . .
- \Large
- * Rejection is the major long-term threat to organ allografts
- ## Allograft rejection remains a major long-term problem
- ![Kidney allograft survival rates in children by transplant year[^3]](graphics/presentation/kidney-graft-survival.png){ height=65% }
- [^3]: Kim & Marks. "Long-term outcomes of children after solid organ transplantation". In: Clinics (2014)
- ## Rejection is treated with immune suppressive drugs
- * To prevent rejection, a graft recipient must take immune suppressive
- drugs for the rest of their life
- * The graft is periodically checked for signs of rejection, and immune
- suppression dosage is adjusted accordingly
- * Immune suppression is a delicate balance: too much leads to immune
- compromise; too little leads to rejection.
- . . .
- * Both diagnosis and treatment present significant challenges
- * Immune memory is a major confounder
- ## My thesis topics
- ### Chapter 2
- Genome-wide epigenetic analysis of H3K4 and H3K27 methylation in naïve
- and memory $\mathsf{CD4}^{+}$ T-cell activation
- ### Chapter 3
- Improving array-based diagnostics for transplant rejection by
- optimizing data preprocessing
- ### Chapter 4
- Globin-blocking for more effective blood RNA-seq analysis in primate
- animal model for experimental graft rejection treatment
- ## Today's focus
- ### Chapter 2
- \Large
- Genome-wide epigenetic analysis of H3K4 and H3K27 methylation in naïve
- and memory $\mathsf{CD4}^{+}$ T-cell activation
- ## Memory cells: faster, stronger, and more independent
- 
- ## Immune memory is a significant contributor to rejection
- 
- # Figure Storage
- ## Slides
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
- <!-- ## Slide -->
- <!--  -->
|